Plenary Lecture at SABCS: Researchers Continue to Explore HER2 Blockade Strategies

Evidence-based clinical practice has evolved and the search for how best to blockade the HER2 receptor in HER2+ breast cancer continues, said Mothaffer Rimawi, MD, of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine in Houston, TX. In a plenary lecture, Dr Rimawi reviewed HER2 therapies for curative intent over the past decade.

 Cancer Therapy Advisor

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.